We have listed 27 substances for evaluation by EU Member States under the Community Rolling Action Plan (CoRAP) for 2026-2028. Seventeen are planned to be evaluated in 2026, including one group. Ten are listed for evaluation in 2027 and 2028.
We will adopt and publish the plan for 2026-2028 in March 2026 following the opinion of the Member State Committee.
Registrants are encouraged to look at the draft list of substances planned for evaluation in 2026 and update their dossiers to include all relevant information before March 2026.
The European Commission has published an updated version of the Q&A Towards a restriction of hexavalent chromium (Cr(VI)) substances.
Accordingly, we will continue processing all applications and review reports for which our scientific committees have already initiated opinion making, to ensure the timely adoption of these opinions. Also, to avoid disruption of access to the EU market, applications for new Cr(VI) uses or users that are not covered by existing authorisations or transitional arrangements will be processed.
Given the ongoing restriction process, we will prioritise applications for substances other than Cr(VI) for future opinion making. This means that opinion making for all other Cr(VI) applications and review reports is suspended until the Cr(VI) substances are removed from the Authorisation List (Annex XIV) and the restriction applies.
This suspension concerns already submitted applications and review reports for which we have not yet issued an invoice. Concerned companies will be informed individually in due course, through their REACH-IT account.
